Panel Discussion: The rise of Quantitative HRMS
In this panel discussion event our panellists will discuss the results from our survey on Quantitative HRMS and provide a comprehensive insight into HRMS quantitation.
Discussions will include a look into current applications of HRMS technology and reflections on this developing technology in the past few years, particularly in the context of quantitative workflows.
What will you learn?
- Molecules analyzed using HRMS
- Applications of HRMS in quantitative and qualitative workflows
- Selection of detection platform
- Advantages and challenges of utilizing HRMS technology
- Future developments of HRMS
Who may this interest?
- CROs, pharmaceutical and biotechnology companies focused on quantitative bioanalysis
- Bioanalytical scientists working in drug discovery and development, small molecule DMPK and biopharmaceutical DMPK
Diego F. Cortes is an R&D Manager with the chromatographic sciences department of PPD® Laboratories’ bioanalytical lab in Richmond, Virginia, USA. Dr. Cortes earned a bachelor’s degree in biology from the Universidad del Valle, Cali, Colombia in 1999 and a Ph.D. in genetics, bioinformatics and computational biology from Virginia Polytechnic Institute and State University, Blacksburg,Virginia, in 2008. He has over 12 years of experience of scientific research in biological sciences, expanding from genomics and bioinformatics, to metabolomics, proteomics, and bioanalysis. He currently manages an R&D team in conducting bioanalytical method research and development primarily for biotherapeutics using LC-MS technologies.
Dr. Russell Mortishire-Smith
Senior Consultant Scientist, Pharmaceutical Business Ops
After a bachelor’s degree in chemistry at the University of Leeds, Russell obtained his doctorate from Cambridge University in natural product isolation and characterization, and followed this with a post-doctoral fellowship at The Scripps Institute, La Jolla using NMR spectroscopy to determine the solution structures of a variety of transcription-regulating proteins. In 1993, he joined Merck & Co’s Neuroscience Research Centre in Harlow, UK, as an analytical scientist, and over the following 13 years had the privilege of working on a wide variety of drug discovery issues, spanning from chemistry support, open access technology for both NMR and LC/MS, metabonomics, and ultimately, drug metabolite characterization, where he took a particular interest in automated approaches to the analysis of high resolution datasets. In 2006, he moved to work for Janssen Pharmaceutica (Beerse, Belgium), as the functional lead for the European Discovery DMPK organization, where his continued interest in the application of high resolution LC/MS led to publications on the use of ion mobility for distinguishing regioisomeric metabolites, and one of the first practical automated approaches for hotspot localization. Following a variety of successful collaborations with Waters Corp. over nearly 20 years, Russell joined Waters in early 2013, supporting Waters’ commitment to developing solutions to fit customer needs.
Yves Le Blanc
Senior Research Scientist
Dr Yves Le Blanc is a Senior Research Scientist as part of the Applied Research Group at SCIEX. His main areas of interest are applications of hybrid MS-based technologies for qualitative and quantitative analysis across various fields. As part of SCIEX, Dr Le Blanc has occupied several roles from application chemist to lab manager as well as technical marketing lead. He has been directly involved in the development and marketing of the API 3000, API 4000, QTRAP based systems as well as TripleTOF 5600 and SelexION since he joined SCIEX in 1995. In recent years, his main area of research have focused on means of gaining selectivity in peptides analysis by extending capabilities of current systems.
Anton Rosenbaum currently a leads the mass spectrometry group within DMPK organization at MedImmune focusing on quantitative bioanalysis of biotherapeutics and identification and quantification of clinically relevant biomarkers. Prior to joining MedImmune, Anton was Senior Scientist at Centers for Therapeutic Innovation at Pfizer Inc. where he led metabolomic research in non alcoholic steatohepatitis. Prior to joining Pfizer, Anton did his postdoctoral training at Genentech Inc. where he championed application of mass isotopomer distribution analysis for the understanding metabolic pathways important in cancer. Anton obtained his PhD in Biochemistry and Structural Biology from the Weill Graduate School of Cornell University where his research focused on chemical biology dissection of intracellular cholesterol homeostasis.